Pfizer Inc. (PFE)
PFE vs. AZN: Which Cancer-Focused Drug Giant Is the Better Pick?
AstraZeneca and Pfizer both boast strong oncology pipelines, but growth paths, dividends and challenges set them apart for investors.
Pfizer: Dividend Cushion Ratio Brings Yield Sustainability Into Question
Pfizer Inc. faces significant uncertainty due to declining COVID-19 sales and potential policy changes. The uncertainties are further compounded by tariff risks and drug pricing policies under the MFN (most favorable nation) framework. A forward dividend yield of 7%+ can help put in a floor for the stock price amid these uncertainties.
Pfizer, Moderna shares plunge on report that Trump officials plan to link 25 child deaths to COVID vaccine
Shares in Pfizer and Moderna fell 3.9% and 7.4%, respectively.
Pfizer, Moderna shares fall on report that Trump officials will link child deaths to Covid shots
Shares of Pfizer and Moderna fell on Friday after a report that Trump administration health officials plan to link Covid vaccines to the deaths of 25 children. The report comes as Health and Human Services Secretary Robert F.
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (September 2025)
Shares of Pfizer ( NYSE: PFE ) gained 4.50% over the past month after losing 6.50% the month prior.
Pfizer's Golden Cross Signals Strength: How to Play the Stock
Pfizer trades above key SMAs with a golden cross, while new drugs and cost cuts drive growth despite looming headwinds.
Pfizer lays off 100 employees in Seattle area
Pfizer laid off 100 employees in Bothell, Wash.
Pfizer's Credibility Discount: A Clear Buying Opportunity
Pfizer is a Buy for medium- to long-term investors, trading at a low P/E and undervalued versus peers, with strong non-COVID growth. Strategic pivots include aggressive R&D, cost-cutting, and the Seagen acquisition, targeting oncology breakthroughs and diversification beyond the patent cliff. Strong Q2 2025 results, raised guidance, and successful Eliquis patent defense support robust financial health and future cash flow.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pfizer: Shares Are Cheap, But They Could Get Even Cheaper Next Year
I remain bearish on Pfizer due to pricing pressures from IRA/340B and a looming 2026 patent cliff, despite Q2 2025 earnings beat. Cost-cutting measures have lifted EPS above expectations and could deliver $7.7B in savings by 2027, but in my view, these are not a substitute for topline growth. IRA Part D redesign and 340B discounts are already pressuring sales (e.g., Nurtec flat yoy despite 47% U.S. market share). I expect more products like Vyndaqel to be pressured.
Pfizer: Stagnation Is An Investment Opportunity
Pfizer offers an attractive near-7% dividend yield, appealing for income-focused investors. Despite recent stagnation, Pfizer has consistently maintained its dividend payout and remains undervalued. The company has a number of exciting drugs ramping up sales to cover the loss of exclusivity risks, and revenue has grown YoY.
Pfizer Oncology Drugs Drive Sales in Q2: Will the Trend Continue?
Pfizer's oncology portfolio, boosted by Seagen and strong drug sales, fuels Q2 growth and positions the company for future cancer treatment gains.
